Altimmune, Inc. $ALT Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its position in Altimmune, Inc. (NASDAQ:ALT) by 70.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,828 shares of the company’s stock after acquiring an additional 10,264 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Altimmune were worth $96,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ALT. GAMMA Investing LLC boosted its holdings in shares of Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock worth $34,000 after purchasing an additional 4,598 shares during the period. Headland Capital LLC acquired a new stake in Altimmune in the first quarter valued at approximately $50,000. Geneos Wealth Management Inc. acquired a new stake in Altimmune in the first quarter valued at approximately $50,000. E Fund Management Co. Ltd. lifted its stake in Altimmune by 20.3% in the first quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $67,000 after acquiring an additional 2,268 shares during the last quarter. Finally, PFG Investments LLC lifted its stake in Altimmune by 31.6% in the first quarter. PFG Investments LLC now owns 17,500 shares of the company’s stock valued at $88,000 after acquiring an additional 4,200 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ALT has been the subject of a number of analyst reports. B. Riley reduced their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. The Goldman Sachs Group upgraded shares of Altimmune to a “strong sell” rating in a research note on Thursday, July 10th. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Friday, June 27th. Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Friday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $17.40.

Altimmune Trading Down 2.0%

Shares of Altimmune stock opened at $3.92 on Monday. The company’s fifty day moving average price is $3.72 and its two-hundred day moving average price is $4.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $11.16. The firm has a market capitalization of $345.98 million, a PE ratio of -3.32 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. On average, analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.